Unsynchronized butyrophilin molecules dictate cancer cell evasion of Vγ9Vδ2 T-cell killing

被引:6
作者
Wu, Zeguang [1 ]
Lamao, Qiezhong [1 ]
Gu, Meichao [1 ]
Jin, Xuanxuan [1 ]
Liu, Ying [1 ]
Tian, Feng [1 ]
Yu, Ying [1 ]
Yuan, Pengfei [2 ]
Gao, Shuaixin [3 ]
Fulford, Thomas S. [4 ]
Uldrich, Adam P. [4 ,5 ]
Wong, Catherine C. L. [6 ]
Wei, Wensheng [1 ]
机构
[1] Peking Univ, Genome Editing Res Ctr,State Key Lab Prot & Plant, Biomed Pioneering Innovat Ctr,Sch Life Sci, Beijing Adv Innovat Ctr Genom,Peking Tsinghua Ctr, Beijing 100871, Peoples R China
[2] EdiGene Inc, Life Sci Pk, Beijing 102206, Peoples R China
[3] Peking Univ, Hlth Sci Ctr, Ctr Precis Med Multi Res, Beijing 100191, Peoples R China
[4] Univ Melbourne, Dept Microbiol & Immunol, Peter Doherty Inst Infect & Immun, Parkville, Vic 3010, Australia
[5] Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic, Australia
[6] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, State Key Lab Complex Severe & Rare Dis, Dept Med Res Ctr,Clin Res Inst,Peking Tsinghua Ctr, Beijing 100871, Peoples R China
基金
中国国家自然科学基金;
关键词
Butyrophilin; V gamma 9V delta 2 T-cell; Cancer-specific immune evasion; Glutaminyl-peptide cyclotransferase-like; Pyrophosphate metabolite; Immunotherapy; PHOSPHORYLATED ANTIGENS; ACTIVATION; GENES; BTN3A1; STIMULATION; RFX; TCR;
D O I
10.1038/s41423-024-01135-z
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
V gamma 9V delta 2 T cells are specialized effector cells that have gained prominence as immunotherapy agents due to their ability to target and kill cells with altered pyrophosphate metabolites. In our effort to understand how cancer cells evade the cell-killing activity of V gamma 9V delta 2 T cells, we performed a comprehensive genome-scale CRISPR screening of cancer cells. We found that four molecules belonging to the butyrophilin (BTN) family, specifically BTN2A1, BTN3A1, BTN3A2, and BTN3A3, are critically important and play unique, nonoverlapping roles in facilitating the destruction of cancer cells by primary V gamma 9V delta 2 T cells. The coordinated function of these BTN molecules was driven by synchronized gene expression, which was regulated by IFN-gamma signaling and the RFX complex. Additionally, an enzyme called QPCTL was shown to play a key role in modifying the N-terminal glutamine of these BTN proteins and was found to be a crucial factor in V gamma 9V delta 2 T cell killing of cancer cells. Through our research, we offer a detailed overview of the functional genomic mechanisms that underlie how cancer cells escape V gamma 9V delta 2 T cells. Moreover, our findings shed light on the importance of the harmonized expression and function of gene family members in modulating T-cell activity.
引用
收藏
页码:362 / 373
页数:12
相关论文
共 50 条
  • [21] Stress-related and homeostatic cytokines regulate Vγ9Vδ2 T-cell surveillance of mevalonate metabolism
    Gruenbacher, Georg
    Nussbaumer, Oliver
    Gander, Hubert
    Steiner, Bernhard
    Leonhartsberger, Nicolai
    Thurnher, Martin
    ONCOIMMUNOLOGY, 2014, 3 (08): : 1 - 12
  • [22] Molecules and mechanisms implicated in the peculiar antigenic activation process of human Vγ9Vδ2T cells
    Harly, Christelle
    Peigne, Cassie-Marie
    Scotet, Emmanuel
    FRONTIERS IN IMMUNOLOGY, 2015, 5
  • [23] Bacterial outer-membrane vesicles promote Vγ9Vδ2 T cell oncolytic activity
    Firth, Jack
    Sun, Jingjing
    George, Vaques
    Huang, Jian-Dong
    Bajaj-Elliott, Mona
    Gustafsson, Kenth
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [24] NLRC5 promotes transcription of BTN3A1-3 genes and Vγ9Vδ2 T cell-mediated killing
    Dang, Anh Thu
    Strietz, Juliane
    Zenobi, Alessandro
    Khameneh, Hanif J.
    Brandl, Simon M.
    Lozza, Laura
    Conradt, Gregor
    Kaufmann, Stefan H. E.
    Reith, Walter
    Kwee, Ivo
    Minguet, Susana
    Chelbi, Sonia T.
    Guarda, Greta
    ISCIENCE, 2021, 24 (01)
  • [25] Autologous Peripheral Vγ9Vδ2 T Cell Synergizes with αβ T Cell Through Antigen Presentation and BTN3A1 Blockade in Immunotherapy of Cervical Cancer
    Wu, Min
    Liu, Jian
    Liu, Liting
    Yang, Yifan
    Liu, Hong
    Yu, Long
    Zeng, Haihong
    Yuan, Shuo
    Xu, Ruiyi
    Liu, Hangyu
    Jiang, Han
    Qu, Shen
    Wang, Liming
    Chen, Ying
    Wang, Jingyu
    Zhang, Yuwei
    He, Shan
    Feng, Ling
    Han, Junyan
    Zeng, Wanjiang
    Wang, Hui
    Huang, Yafei
    ADVANCED SCIENCE, 2025,
  • [26] Role of Vγ9vδ2 T lymphocytes in infectious diseases
    Gay, Laetitia
    Mezouar, Soraya
    Cano, Carla
    Frohna, Paul
    Madakamutil, Loui
    Mege, Jean-Louis
    Olive, Daniel
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [27] Glycolysis inhibition affects proliferation and cytotoxicity of Vγ9Vδ2 T cells expanded for adoptive cell therapy
    Aehnlich, Pia
    Santiago, Marta Velasco
    Dam, Soren Helweg
    Salo, Sara Fresnillo
    Rahbech, Anne
    Olsen, Lars Ronn
    Straten, Per thor
    Desler, Claus
    Olofsson, Gitte Holmen
    CYTOTHERAPY, 2024, 26 (09) : 1033 - 1045
  • [28] Butyrophilin-2A1 Directly Binds Germline-Encoded Regions of the Vγ9Vδ2 TCR and Is Essential for Phosphoantigen Sensing
    Karunakaran, Mohindar M.
    Willcox, Carrie R.
    Salim, Mahboob
    Paletta, Daniel
    Fichtner, Alina S.
    Noll, Angela
    Starick, Lisa
    Noehren, Anna
    Begley, Charlotte R.
    Berwick, Katie A.
    Chaleil, Raphael A. G.
    Pitard, Vincent
    Dechanet-Merville, Julie
    Bates, Paul A.
    Kimmel, Brigitte
    Knowles, Timothy J.
    Kunzmann, Volker
    Walter, Lutz
    Jeeves, Mark
    Mohammed, Fiyaz
    Willcox, Benjamin E.
    Herrmann, Thomas
    IMMUNITY, 2020, 52 (03) : 487 - +
  • [29] Chemotherapy and zoledronate sensitize solid tumour cells to Vγ9Vδ2 T cell cytotoxicity
    Mattarollo, Stephen R.
    Kenna, Tony
    Nieda, Mie
    Nicol, Andrew J.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (08) : 1285 - 1297
  • [30] Chemotherapy and zoledronate sensitize solid tumour cells to Vγ9Vδ2 T cell cytotoxicity
    Stephen R. Mattarollo
    Tony Kenna
    Mie Nieda
    Andrew J. Nicol
    Cancer Immunology, Immunotherapy, 2007, 56 : 1285 - 1297